Department of Urology, Aristotle University of Thessaloniki, Thessaloniki 54635, Greece.
Institute for the Study of Urological Diseases, Thessaloniki 54622, Greece.
J Sex Med. 2024 May 28;21(6):533-538. doi: 10.1093/jsxmed/qdae038.
Patients with severe erectile dysfunction (ED) remain the most challenging group in terms of available noninvasive treatment modalities.
The study sought to assess the role of combination therapy with low-intensity shockwave therapy (LiST) and daily tadalafil 5 mg in a highly select group of patients with severe vasculogenic ED through a double-blind, randomized trial.
Forty-eight sexually active men were randomly assigned to 12 sessions of LiST 3 times weekly and tadalafil 5 mg once daily (n = 34) or sham therapy and tadalafil (n = 17) for 4 weeks. Patients were assessed at 1 and 3 months after completion of treatment.
Improvement of erectile function was evaluated through the International Index of Erectile Function-Erectile Function domain (IIEF-EF) or 6-item IIEF and the Sexual Encounter Profile (SEP) diary. The primary outcome was the difference between the groups in the IIEF-EF at 3 months after completion of treatment. Secondary outcomes comprised (1) the difference between the groups in the IIEF-EF at 1 month after completion of treatment, (2) the difference between the groups in the "yes" responses to question 3 of the SEP diary at 1 and 3 months, and (3) the treatment-related adverse events. The number of patients attaining a minimal clinically important difference in the IIEF-EF (improvement of at least 7 points) was also assessed.
After treatment, the absolute scores in the IIEF-EF were higher in patients receiving LiST and tadalafil vs sham therapy and tadalafil both at the 1-month (12.1 ± 2.4 vs 10.2 ± 1.7; P = .002) and at the 3-month (12.9 ± 2.1 vs 10.8 ± 1.8; P < .001) evaluation. Between the 2 groups, the proportion of "yes" responses to question 3 of the SEP diary was not statistically significant, whereas the number of patients attaining a minimal clinically important difference in the IIEF-EF was statistically significant only at the 3-month evaluation. No adverse events occurred.
Application of LiST in patients with severe vasculogenic ED receiving daily dose tadalafil may further improve erectile function compared with tadalafil as a stand-alone treatment on the short term.
Although we provided the first study in the field, severe vasculogenic ED was defined based on medical history and clinical examination and not based on penile ultrasound measures.
The combination of 12 sessions LiST 3 times weekly and daily tadalafil for 4 weeks led to a 2-point difference in the IIEF-EF compared with sham therapy and daily tadalafil among patients with severe vasculogenic ED after 1 and 3 months from completion of treatment.
在现有的非侵入性治疗方法中,严重勃起功能障碍(ED)患者仍然是最具挑战性的群体。
本研究旨在通过一项双盲、随机试验,评估低强度冲击波治疗(LiST)联合每日他达拉非 5mg 治疗在一组严重血管性 ED 高度选择患者中的作用。
48 名有性生活的男性被随机分配接受 12 次 LiST,每周 3 次,同时每日服用他达拉非 5mg(n=34)或假治疗和他达拉非(n=17)4 周。治疗结束后 1 个月和 3 个月进行评估。
通过国际勃起功能指数-勃起功能域(IIEF-EF)或 6 项 IIEF 和性遭遇剖面图(SEP)日记评估勃起功能的改善。主要结局是治疗结束后 3 个月时两组 IIEF-EF 的差异。次要结局包括(1)治疗结束后 1 个月时两组 IIEF-EF 的差异,(2)两组在 SEP 日记第 3 个问题“是”回答的差异,(3)与治疗相关的不良事件。还评估了 IIEF-EF 中最小临床重要差异(至少改善 7 分)的患者人数。
治疗后,接受 LiST 和他达拉非治疗的患者 IIEF-EF 的绝对评分在 1 个月(12.1±2.4 对 10.2±1.7;P=0.002)和 3 个月(12.9±2.1 对 10.8±1.8;P<.001)时均高于接受假治疗和他达拉非治疗的患者。两组在 SEP 日记第 3 个问题“是”回答的比例无统计学意义,但只有在 3 个月时,达到 IIEF-EF 最小临床重要差异的患者数量才有统计学意义。未发生不良事件。
在接受每日剂量他达拉非治疗的严重血管性 ED 患者中应用 LiST 可能会在短期内进一步改善勃起功能,而与单独使用他达拉非治疗相比。
尽管我们提供了该领域的第一项研究,但严重血管性 ED 是基于病史和临床检查定义的,而不是基于阴茎超声测量。
在治疗结束后 1 和 3 个月,与假治疗和每日他达拉非治疗相比,每周接受 3 次 LiST 治疗 12 次联合每日他达拉非治疗 4 周,可使 IIEF-EF 平均提高 2 分。